Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In recent years, NUCB2/Nesfatin-1 (NES-1) has been reported to have multifaceted actions beyond being a novel satiety factor, including regulation of gastrointestinal function, glucose and lipid metabolism, cardiovascular system regulation, and protective effects on the kidney during ischemia-reperfusion. We have reported that serum NES-1 (sNES-1) concentration. in DKD, negatively correlates with tubular histological damage and positively correlates with renal prognosis. Furthermore, elderly DKD patients aged over 70 years significantly lower sNES-1 and more severe tubular histological damage compared to DKD patients under 70 years of age. It remains unclear how sNES-1 influences the disease activity of diabetic nephropathy. Therefore, we investigated the effect of sNES-1 on factors related to diabetic nephropathy disease activity.
We measured sNES-1 using an ELISA assay in 56 patients diagnosed with DKD, including diabetic nephropathy, who underwent renal biopsy at Kindai University hospital between January 2013 and December 2023. Participants were divided into three groups based on sNES-1 levels: high group (>1500 pg/ml), normal group (500–1500 pg/ml), and low group (<500 pg/ml). Six participants (3 men, 3 women) were randomly selected from each group. and low group (<500 pg/ml). Six patients (3 males, 3 females) were randomly selected from each group. Serum and urine samples from these patients were analyzed and compared using LC-MS/MS (DDA and DIA method).
LC-MS/MS results showed significant differences in protein expression in serum: 2 factors between the normal group and the high group, 13 factors between the normal group and the low group, and 15 factors between the high group and the low group. In urine, significant differences were observed in protein expression: 8 factors between the normal group and the high group, 10 factors between the normal group and the low group, and 15 factors between the high group and the low group. Specifically, in serum, VAP1 (Vascular cell adhesion protein 1) and Cadherin-5 were low in the sNES-1 low group. In urine, ICOS ligand (Inducible T-cell Co-Stimulator Ligand) and vasorin were low in the sNES-1 low group. Furthermore, compared to the sNES-1 normal group, the sNES-1 high group showed elevated levels of LASP1 (LIM and SH3 domain protein 1) and 28S ribosomal protein S12. Analysis of serum and urine samples revealed no significant differences based on gender.
In DKD patients, low sNES-1 levels indicate reduced VAP-1 levels—a marker of diabetic vascular complications—suggesting potential progression of diabetic vascular complications. Additionally, low cadherin levels imply weakened tubular epithelial cell adhesion, compromised intercellular barriers, and increased inflammation and fibrosis, indicating possible progression of tubular dysfunction.In urine, vasorin, which provides renal protection from ischemia-reperfusion by regulating the HIF-1α/MAPK signaling pathway, was low. This suggests the potential for progression of renal damage (particularly tubular), anemia, and possible influence on ICOS ligand signaling, one mechanism underlying cardiovascular complications in type 2 diabetes patients. It is thought that sNES-1 could potentially become a new therapeutic target for diabetic nephropathy in the future.
